Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study.

ABSTRACT:

Background and objectives

We assessed the safety, tolerability, and preliminary efficacy of nabilone, a cannabinoid agonist, to treat cannabis dependence.

Methods

Eighteen adults with DSM-IV cannabis dependence were randomized to receive either 2 mg/day of nabilone (n = 10) or placebo (n = 8) for 10 weeks in addition to medication management. Twelve participants, six in each group, completed treatment. The safety and tolerability of nabilone was assessed at each visit. Any side effects from nabilone or the placebo were documented. Cannabis use outcomes were assessed via self-report of days of use and twice-weekly urine cannabinoid tests; secondary outcomes included cannabis craving and anxiety.

Results

We assessed safety and tolerability at each study visit. A total o

SUBMITTER: Hill KP 

PROVIDER: S-EPMC5699926 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature